Skip to main content
SpringerLink
Log in

Neurologic Complications of Chemotherapy

  • Chapter
Cancer Neurology In Clinical Practice

Summary

Neurotoxicity associated with chemotherapy is a common complication of many anticancer agents and frequently constitutes a dose-limiting toxicity. There is a wide range of adverse effects including short-term and long-term complications. With the recent use of more aggressive treatment regimens and prolonged survival of cancer patients, neurologic complications of chemotherapy have been observed with increasing frequency. As a result, the nervous system may be more vulnerable than previously thought, and neurotoxicity may not always be reversible after discontinuation of treatment. Both the central and the peripheral nervous system can be affected. It is critical for the oncologist to recognize treatment-related side effects early and to distinguish these from symptoms related to the progression of the disease. This chapter will discuss the neurotoxic side effect profile of commonly used antineoplastic agents, including traditional cytotoxic agents, hormonal agents, monoclonal antibodies and small molecule inhibitors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Dietrich J., Han R., Yang Y et al. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol 2006;5(7):22.

    Google Scholar 

  2. Johnson SW, Stevenson JP, O’Dwyer PJ. Cisplatin and its analogues. In: Devita VT, Hellman S, Rosenberg SA, (eds.). Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott, Williams and Wilkins; 2001:376–388.

    Google Scholar 

  3. Gormley PE, Gangji D, Wood, JH et al. Pharmacokinetic study of cerebrospinal fluid penetration of cis-diamminedichloroplatinum (II). Cancer Chemother Pharmacol 1981;5(4):257–260.

    Article  PubMed  CAS  Google Scholar 

  4. Gregg RW, Molepo JM, Monpetit VJ et al. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 1992;10(5):795–803.

    PubMed  CAS  Google Scholar 

  5. DeGregorio M, Wilbur B, King O et al. Peak cerebrospinal fluid platinum levels in a patient with ependymoma: evaluation of two different methods of cisplatin administration. Cancer Treat Rep 1986;70(12):1437–1438.

    PubMed  CAS  Google Scholar 

  6. Roelofs RI, Hrushesky W, Rogin J et al. Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology 1984;34(7):934–938.

    PubMed  CAS  Google Scholar 

  7. Thompson SW, Davis LE, Kornfeld M et al. Cisplatin neuropathy: clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 1984;54(7):1269–1275.

    Article  PubMed  CAS  Google Scholar 

  8. Allen JC. The neurotoxicity of cisplatin. In: Rottenberg, DA (ed.). Neurologic Complications of Cancer Treatment. Boston: Butterworth-Heinemann; 1991:135–142.

    Google Scholar 

  9. Pietrangeli A, Leandri M, Terzoli E et al. Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up. Eur Neurol 2006;56(1):13–16.

    Article  PubMed  CAS  Google Scholar 

  10. van der Hoop RG., van der Burg ME, ten Bokkel Huinink WW et al. Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin. Cancer 1990;66(8):1697–1702.

    Article  PubMed  Google Scholar 

  11. van der Hoop RG, Vecht CJ, van der Burg ME et al. Prevention of cisplatin neurotoxicity with an ACTH(4–9) analogue in patients with ovarian cancer. N Engl J Med 1990;322(2):89–94.

    PubMed  Google Scholar 

  12. Siegal T, Haim, N. Cisplatin-induced peripheral neuropathy: frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer 1990;66(6):1117–1123.

    Article  PubMed  CAS  Google Scholar 

  13. Mollman JE, Glover DJ, Hogan WM et al. Cisplatin neuropathy: risk factors, prognosis, and protection by WR-2721. Cancer 1988;61(11):2192–2195.

    Article  PubMed  CAS  Google Scholar 

  14. Kemp G, Rose P, Lurain J et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996;14(7):2101–2112.

    PubMed  CAS  Google Scholar 

  15. Argyriou AA, Chroni E, Koutras A et al. A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results. Support Care Cancer 2006;14(11):1134–1140.

    Article  PubMed  Google Scholar 

  16. Feinberg WM, Swenson MR. Cerebrovascular complications of l-asparaginase therapy. Neurology 1988;38(1):127–133.

    PubMed  CAS  Google Scholar 

  17. Forsyth PA, Cascino TL. Neurologic complications of chemotherapy. In: Dekker M (ed.). Neurologic Complications of Cancer. New York: Wiley; 1995:241–266.

    Google Scholar 

  18. Gilbert MR. The neurotoxicity of chemotherapy. Neurologist 1998;4:43–53.

    Article  Google Scholar 

  19. Posner JB. Side effects of chemotherapy. In: Posner JB (ed.). Neurologic Complications of Cancer. Philadelphia: F.A. Davis; 1995:282–310.

    Google Scholar 

  20. Robertson GL, Bhoopalam N, Zelkowitz LJ. Vincristine neurotoxicity and abnormal secretion of antidiuretic hormone. Arch Intern Med 1973;132(5):717–720.

    Article  PubMed  CAS  Google Scholar 

  21. Rottenberg DA. Neurological Complications of Cancer Treatment. Boston: Butterworth-Heinemann; 1991.

    Google Scholar 

  22. Gerritsen van der Hoop R, de Koning P, Boven E et al. Efficacy of the neuropeptide ORG.2766 in the prevention and treatment of cisplatin-induced neurotoxicity in rats. Eur J Cancer Clin Oncol 1988;24(4):637–642.

    Google Scholar 

  23. Gerritsen van der Hoop R, Hamers FP, Neijt JP et al. Protection against cisplatin-induced neurotoxicity by ORG 2766: histological and electrophysiological evidence. J Neurol Sci 1994;126(2):109–115.

    Google Scholar 

  24. Moroso MJ, Blair RL. A review of cis-platinum ototoxicity. J Otolaryngol 1983;12(6):365–369.

    PubMed  CAS  Google Scholar 

  25. Schell MJ, McHaney VA, Green AA et al. Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. J Clin Oncol 1989;7(6):754–760.

    PubMed  CAS  Google Scholar 

  26. Walsh TJ, Clark AW, Parhad IM et al. Neurotoxic effects of cisplatin therapy. Arch Neurol 1982;39(11):719–720.

    PubMed  CAS  Google Scholar 

  27. Zheng JL, Stewart RR, and Gao WQ. Neurotrophin-4/5 enhances survival of cultured spiral ganglion neurons and protects them from cisplatin neurotoxicity. J Neurosci 1995;15(7 Pt 2):5079–5087.

    PubMed  CAS  Google Scholar 

  28. Oldenburg J, Kraggerud SM, Cvancarova M et al. Cisplatin-induced long-term hearing impairment is associated with specific glutathione S-transferase genotypes in testicular cancer survivors. J Clin Oncol 2007;25(6):708–714.

    Article  PubMed  CAS  Google Scholar 

  29. Black FO., Myers EN, Schramm VL et al. Cisplatin vestibular ototoxicity: preliminary report. Laryngoscope 1982;92(12):1363–1368.

    PubMed  CAS  Google Scholar 

  30. Frustaci S, Barzan L, Comoretto R et al. Local neurotoxicity after intra-arterial cisplatin in head and neck cancer. Cancer Treat Rep 1987;71(3):257–259.

    PubMed  CAS  Google Scholar 

  31. Kupersmith MJ, Frohman LP, Choi IS et al. Visual system toxicity following intra-arterial chemotherapy. Neurology 1988;38(2):284–289.

    PubMed  CAS  Google Scholar 

  32. Ostrow S, Hahn D, Wiernik PH et al. Ophthalmologic toxicity after cis-dichlorodiammineplatinum(II) therapy. Cancer Treat Rep 1978;62(10):1591–1594.

    PubMed  CAS  Google Scholar 

  33. Wilding G, Caruso R, Lawrence TS et al. Retinal toxicity after high-dose cisplatin therapy. J Clin Oncol 1985;3(12):1683–1689.

    PubMed  CAS  Google Scholar 

  34. Tfayli A, Hentschel P, Madajewicz S et al. Toxicities related to intra-arterial infusion of cisplatin and etoposide in patients with brain tumors. J Neurooncol 1999;42(1):73–77.

    Article  PubMed  CAS  Google Scholar 

  35. List AF, Kummet TD. Spinal cord toxicity complicating treatment with cisplatin and etoposide. Am J Clin Oncol 1990;13(3):256–258.

    Article  PubMed  CAS  Google Scholar 

  36. Walther PJ, Rossitch E, Jr., Bullard DE. The development of Lhermitte’s sign during cisplatin chemotherapy: possible drug-induced toxicity causing spinal cord demyelination. Cancer 1987;60(9):2170–2172.

    Article  PubMed  CAS  Google Scholar 

  37. Berman IJ, Mann MP. Seizures and transient cortical blindness associated with cis-platinum (II) diamminedichloride (PDD) therapy in a thirty-year-old man. Cancer 1980;45(4):764–766.

    Article  PubMed  CAS  Google Scholar 

  38. Ito Y, Arahata Y, Goto, Y et al. Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. AJNR Am J Neuroradiol 1998;19(3):415–417.

    PubMed  CAS  Google Scholar 

  39. Lyass O, Lossos A, Hubert A et al. Cisplatin-induced nonconvulsive encephalopathy. Anticancer Drugs 1998;9(1):100–104.

    Article  PubMed  CAS  Google Scholar 

  40. Newton HB, Page MA, Junck L et al. Intra-arterial cisplatin for the treatment of malignant gliomas. J Neuro-oncol 1989;7(1):39–45.

    Article  CAS  Google Scholar 

  41. Walker RW, Cairncross JG, Posner JB. Cerebral herniation in patients receiving cisplatin. J Neurooncol 1988;6(1):61–65.

    Article  PubMed  CAS  Google Scholar 

  42. Bellin SL, Selim M. Cisplatin-induced hypomagnesemia with seizures: a case report and review of the literature. Gynecol Oncol 1988;30(1):104–113.

    Article  PubMed  CAS  Google Scholar 

  43. Schilsky RL, Anderson T. Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med 1979;90(6):929–931.

    PubMed  CAS  Google Scholar 

  44. Ritch PS. Cis-dichlorodiammineplatinum II–induced syndrome of inappropriate secretion of antidiuretic hormone. Cancer 1988;61(3):448–450.

    Article  PubMed  CAS  Google Scholar 

  45. Dietrich J, Marienhagen J, Schalke B et al. Vascular neurotoxicity following chemotherapy with cisplatin, ifosfamide, and etoposide. Ann Pharmacother 2004;38(2):242–246.

    PubMed  Google Scholar 

  46. Gerl A, Clemm C, Wilmanns W. Acute and late vascular complications following chemotherapy for germ cell tumors. Onkologie 1993;16:88–92.

    Google Scholar 

  47. Icli F, Karaoguz H, Dincol D et al. Severe vascular toxicity associated with cisplatin-based chemotherapy. Cancer 1993;72(2):587–593.

    Article  PubMed  CAS  Google Scholar 

  48. Gerl A. Vascular toxicity associated with chemotherapy for testicular cancer. Anticancer Drugs 1994;5(6):607–614.

    Article  PubMed  CAS  Google Scholar 

  49. Samuels BL, Vogelzang NJ, Kennedy BJ. Severe vascular toxicity associated with vinblastine, bleomycin, and cisplatin chemotherapy. Cancer Chemother Pharmacol 1987;19(3):253–256.

    Article  PubMed  CAS  Google Scholar 

  50. El Amrani M, Heinzlef O, Debroucker T et al. Brain infarction following 5-fluorouracil and cisplatin therapy. Neurology 1998;51(3):899–901.

    PubMed  CAS  Google Scholar 

  51. Troy L, McFarland K, Littman-Power S et al. Cisplatin-based therapy: a neurological and neuropsychological review. Psycho-oncology 2000;9(1):29–39.

    Article  PubMed  CAS  Google Scholar 

  52. Glantz MJ, LaFollette S, Jaeckle KA et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999;17(10):3110–3116.

    PubMed  CAS  Google Scholar 

  53. Herzig RH, Hines JD, Herzig GP et al. Cerebellar toxicity with high-dose cytosine arabinoside. J Clin Oncol 1987;5(6):927–932.

    PubMed  CAS  Google Scholar 

  54. Hwang TL, Yung WK, Estey EH et al. Central nervous system toxicity with high-dose Ara-C. Neurology 1985;35(10):1475–1479.

    PubMed  CAS  Google Scholar 

  55. Winkelman MD, Hines JD. Cerebellar degeneration caused by high-dose cytosine arabinoside: a clinicopathological study. Ann Neurol 1983;14(5):520–527.

    Article  PubMed  CAS  Google Scholar 

  56. Lazarus HM, Herzig RH, Herzig GP et al. Central nervous system toxicity of high-dose systemic cytosine arabinoside. Cancer 1981;48(12):2577–2582.

    Article  PubMed  CAS  Google Scholar 

  57. Eden OB, Goldie W, Wood T et al. Seizures following intrathecal cytosine arabinoside in young children with acute lymphoblastic leukemia. Cancer 1978;42(1):53–58.

    Article  PubMed  CAS  Google Scholar 

  58. Gottlieb D, Bradstock K, Koutts J et al. The neurotoxicity of high-dose cytosine arabinoside is age-related. Cancer 1987;60(7):1439–1441.

    Article  PubMed  CAS  Google Scholar 

  59. Damon LE, Mass R, Linker CA. The association between high-dose cytarabine neurotoxicity and renal insufficiency. J Clin Oncol 1989;7(10):1563–1568.

    PubMed  CAS  Google Scholar 

  60. Saito B, Nakamaki T, Nakashima H et al. Reversible posterior leukoencephalopathy syndrome after repeat intermediate-dose cytarabine chemotherapy in a patient with acute myeloid leukemia. Am J Hematol 2007;82(4):304–306.

    Article  PubMed  Google Scholar 

  61. Smith GA, Damon LE, Rugo HS et al. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. J Clin Oncol 1997;15(2):833–839.

    PubMed  CAS  Google Scholar 

  62. Ritch PS, Hansen RM, Heuer DK. Ocular toxicity from high-dose cytosine arabinoside. Cancer 1983;51(3):430–432.

    Article  PubMed  CAS  Google Scholar 

  63. Shaw PJ, Procopis PG, Menser MA et al. Bulbar and pseudobulbar palsy complicating therapy with high-dose cytosine arabinoside in children with leukemia. Med Pediatr Oncol 1991;19(2):122–125.

    Article  PubMed  CAS  Google Scholar 

  64. Nevill TJ, Benstead TJ, McCormick CW et al. A. Horner’s syndrome and demyelinating peripheral neuropathy caused by high-dose cytosine arabinoside. Am J Hematol 1989;32(4):314–315.

    Article  PubMed  CAS  Google Scholar 

  65. Hoffman DL, Howard JR, Jr., Sarma R et al. Encephalopathy, myelopathy, optic neuropathy, and anosmia associated with intravenous cytosine arabinoside. Clin Neuropharmacol 1993;16(3):258–262.

    Article  PubMed  CAS  Google Scholar 

  66. Jabbour E, O’Brien S, Kantarjian H et al. Neurological complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 2007;109(8):3214–3218.

    Article  PubMed  CAS  Google Scholar 

  67. van den Berg H, van der Flier M, van de Wetering MD. Cytarabine-induced aseptic meningitis. Leukemia 2001;15(4):697–699.

    Article  PubMed  Google Scholar 

  68. Kleinschmidt-DeMasters BK, Yeh M. “Locked–in syndrome” after intrathecal cytosine arabinoside therapy for malignant immunoblastic lymphoma. Cancer 1992;70(10):2504–2507.

    Article  PubMed  CAS  Google Scholar 

  69. Luque FA, Selhorst JB, Petruska P. Parkinsonism induced by high-dose cytosine arabinoside. Mov Disord 1987;2(3):219–222.

    Article  PubMed  CAS  Google Scholar 

  70. Hammack JE, Cascino TL. Chemotherapy and other common drug-induced toxicities of the central nervous system in patients with cancer. In: Vecht CJ, (ed.). Handbook of Clinical Neurology. Amsterdam: Elsevier Science; 1998:481–514.

    Google Scholar 

  71. Phillips PC, Reinhard CS. Antipyrimidine neurotoxicity: cytosine arabinoside and 5-fluorouracil. In: Rottenberg DA, (ed.) Neurologic Complications of Cancer Treatment. Boston: Butterworth-Heinemann; 1991:97–114.

    Google Scholar 

  72. Dunton SF, Nitschke R, Spruce WE et al. Progressive ascending paralysis following administration of intrathecal and intravenous cytosine arabinoside: a Pediatric Oncology Group study. Cancer 1986;57(6):1083–1088.

    Article  PubMed  CAS  Google Scholar 

  73. Resar LM, Phillips PC, Kastan MB et al. Acute neurotoxicity after intrathecal cytosine arabinoside in two adolescents with acute lymphoblastic leukemia of B-cell type. Cancer 1993;71(1):117–123.

    Article  PubMed  CAS  Google Scholar 

  74. Russell JA, Powles RL. Letter: neuropathy due to cytosine arabinoside. Br Med J 1974;4(5945):652–653.

    PubMed  CAS  Google Scholar 

  75. Borgeat A, De Muralt B, Stalder M. Peripheral neuropathy associated with high-dose Ara-C therapy. Cancer 1986;58(4):852–854.

    Article  PubMed  CAS  Google Scholar 

  76. Saito T, Asai O, Dobashi N et al. Peripheral neuropathy caused by high-dose cytosine arabinoside treatment in a patient with acute myeloid leukemia. J Infect Chemother 2006;12(3):148–151.

    Article  PubMed  Google Scholar 

  77. Powell BL, Capizzi RL, Lyerly ES et al. Peripheral neuropathy after high-dose cytosine arabinoside, daunorubicin, and asparaginase consolidation for acute nonlymphocytic leukemia. J Clin Oncol 1986;4(1):95–97.

    PubMed  CAS  Google Scholar 

  78. Osborne WL, Holyoake TL, McQuaker IG et al. Fatal peripheral neuropathy following FLA chemotherapy. Clin Lab Haematol 2004;26(4):295–296.

    Article  PubMed  CAS  Google Scholar 

  79. Openshaw H, Slatkin NE, Stein AS et al. Acute polyneuropathy after high-dose cytosine arabinoside in patients with leukemia. Cancer 1996;78(9):1899–1905.

    Article  PubMed  CAS  Google Scholar 

  80. Paul M, Joshua D, Rahme N et al. Fatal peripheral neuropathy associated with axonal degeneration after high-dose cytosine arabinoside in acute leukaemia. Br J Haematol 1991;79(3):521–523.

    Article  PubMed  CAS  Google Scholar 

  81. Scherokman B, Filling-Katz MR, Tell D. Brachial plexus neuropathy following high-dose cytarabine in acute monoblastic leukemia. Cancer Treat Rep 1985;69(9):1005–1006.

    PubMed  CAS  Google Scholar 

  82. Geller HM, Cheng KY, Goldsmith NK et al. Oxidative stress mediates neuronal DNA damage and apoptosis in response to cytosine arabinoside. J Neurochem 2001;78(2):265–275.

    Article  PubMed  CAS  Google Scholar 

  83. Koros C, Papalexi E, Anastasopoulos D et al. Effects of Ara-C treatment on motor coordination and cerebellar cytoarchitecture in the adult rat: a possible protective role of NAC. Neurotoxicology 2007;28(1):83–92.

    Article  PubMed  CAS  Google Scholar 

  84. Courtney MJ, Coffey ET. The mechanism of Ara-C-induced apoptosis of differentiating cerebellar granule neurons. Eur J Neurosci 1999;11(3):1073–1084.

    Article  PubMed  CAS  Google Scholar 

  85. Dworkin LA, Goldman RD, Zivin LS et al. Cerebellar toxicity following high-dose cytosine arabinoside. J Clin Oncol 1985;3(5):613–616.

    PubMed  CAS  Google Scholar 

  86. Meanwell CA, Blake AE, Kelly KA et al. Prediction of ifosfamide/mesna associated encephalopathy. Eur J Cancer Clin Oncol 1986;22(7):815–819.

    Article  PubMed  CAS  Google Scholar 

  87. Zalupski M, Baker LH. Ifosfamide. J Natl Cancer Inst 1988;80(8):556–566.

    Article  PubMed  CAS  Google Scholar 

  88. Pratt CB, Goren MP, Meyer WH et al. Ifosfamide neurotoxicity is related to previous cisplatin treatment for pediatric solid tumors. J Clin Oncol 1990;8(8):1399–1401.

    PubMed  CAS  Google Scholar 

  89. Dechant KL, Brogden RN, Pilkington T et al. Ifosfamide/mesna: a review of its antineoplastic activity, pharmacokinetic properties, and therapeutic efficacy in cancer. Drugs 1991;42(3):428–467.

    PubMed  CAS  Google Scholar 

  90. Cerny T, Kupfer A. The enigma of ifosfamide encephalopathy. Ann Oncol 1992;3(9):679–681.

    PubMed  CAS  Google Scholar 

  91. Fleming RA. An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy 1997;17(5 Pt 2):146S–154S.

    PubMed  CAS  Google Scholar 

  92. Miller LJ, Eaton VE. Ifosfamide-induced neurotoxicity: a case report and review of the literature. Ann Pharmacother 1992;26(2):183–187.

    PubMed  CAS  Google Scholar 

  93. Primavera A, Audenino D, Cocito L. Ifosfamide encephalopathy and nonconvulsive status epilepticus. Can J Neurol Sci 2002;29(2):180–183.

    PubMed  Google Scholar 

  94. Watkin SW, Husband DJ, Green JA et al. Ifosfamide encephalopathy: a reappraisal. Eur J Cancer Clin Oncol 1989;25(9):1303–1310.

    Article  PubMed  CAS  Google Scholar 

  95. Pratt CB, Green AA, Horowitz ME et al. Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna. J Clin Oncol 1986;4(8):1253–1261.

    PubMed  CAS  Google Scholar 

  96. David KA, Picus J. Evaluating risk factors for the development of ifosfamide encephalopathy. Am J Clin Oncol 2005;28(3):277–280.

    Article  PubMed  CAS  Google Scholar 

  97. Curtin JP, Koonings PP, Gutierrez M et al. Ifosfamide-induced neurotoxicity. Gynecol Oncol 1991;42(3):193–196; discussion 1–2.

    Article  PubMed  CAS  Google Scholar 

  98. Chastagner P, Sommelet-Olive D, Kalifa C et al. Phase II study of ifosfamide in childhood brain tumors: a report by the French Society of Pediatric Oncology (SFOP). Med Pediatr Oncol 1993;21(1):49–53.

    Article  PubMed  CAS  Google Scholar 

  99. Ghosn M, Carde P, Leclerq B et al. Ifosfamide/mesna related encephalopathy: a case report with a possible role of phenobarbital in enhancing neurotoxicity. Bull Cancer 1988;75(4):391–392.

    PubMed  CAS  Google Scholar 

  100. Aeschlimann C, Cerny T, Kupfer A. Inhibition of (mono)amine oxidase activity and prevention of ifosfamide encephalopathy by methylene blue. Drug Metab Dispos 1996;24(12):1336–1339.

    PubMed  CAS  Google Scholar 

  101. Pelgrims J, De Vos F, Van den Brande J et al. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer 2000;82(2):291–294.

    Article  PubMed  CAS  Google Scholar 

  102. Turner AR, Duong CD, Good DJ. Methylene blue for the treatment and prophylaxis of ifosfamide-induced encephalopathy. Clin Oncol (R Coll Radiol) 2003;15(7):435–439.

    CAS  Google Scholar 

  103. Patel PN. Methylene blue for management of ifosfamide-induced encephalopathy. Ann Pharmacother 2006;40(2):299–303.

    Article  PubMed  CAS  Google Scholar 

  104. Simonian NA, Gilliam FG, Chiappa KH. Ifosfamide causes a diazepam-sensitive encephalopathy. Neurology 1993;43(12):2700–2702.

    PubMed  CAS  Google Scholar 

  105. Verdeguer A, Castel V, Esquembre C et al. Fatal encephalopathy with ifosfamide/mesna. Pediatr Hematol Oncol 1989;6(4):383–385.

    Article  PubMed  CAS  Google Scholar 

  106. Shuper A, Stein J, Goshen J et al. Subacute central nervous system degeneration in a child: an unusual manifestation of ifosfamide intoxication. J Child Neurol 2000;15(7):481–483.

    Article  PubMed  CAS  Google Scholar 

  107. Geiser CF, Bishop Y, Jaffe N 3rd et al., Adverse effects of intrathecal methotrexate in children with acute leukemia in remission. Blood 1975;45(2):189–195.

    PubMed  CAS  Google Scholar 

  108. Glantz MJ, Jaeckle KA, Chamberlain MC et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 1999;5(11):3394–3402.

    PubMed  CAS  Google Scholar 

  109. Phillips J. Methotrexate toxicity. In: Rottenberg DA (ed.). Neurologic Complications of Cancer Treatment. Boston: Butterworth-Heinemann; 1991:115–134.

    Google Scholar 

  110. Boogerd W, Sande JJ vd, Moffie D. Acute fever and delayed leukoencephalopathy following low-dose intraventricular methotrexate. J Neurol Neurosurg Psychiatry 1988;51(10):1277–1283.

    Google Scholar 

  111. Bates S, McKeever P, Masur H et al. Myelopathy following intrathecal chemotherapy in a patient with extensive Burkitt’s lymphoma and altered immune status. Am J Med 1985;78(4):697–702.

    Article  PubMed  CAS  Google Scholar 

  112. McLean DR, Clink HM, Ernst P et al. Myelopathy after intrathecal chemotherapy: a case report with unique magnetic resonance imaging changes. Cancer 1994;73(12):3037–3040.

    Article  PubMed  CAS  Google Scholar 

  113. Gagliano RG, Costanzi JJ. Paraplegia following intrathecal methotrexate: report of a case and review of the literature. Cancer 1976;37(4):1663–1668.

    Article  PubMed  CAS  Google Scholar 

  114. Clark AW, Cohen SR, Nissenblatt MJ et al. Paraplegia following intrathecal chemotherapy: neuropathologic findings and elevation of myelin basic protein. Cancer 1982;50(1):42–47.

    Article  PubMed  CAS  Google Scholar 

  115. Shapiro WR, Chernik NL, Posner JB. Necrotizing encephalopathy following intraventricular instillation of methotrexate. Arch Neurol 1973;28(2):96–102.

    PubMed  CAS  Google Scholar 

  116. Lemann W, Wiley RG, Posner, JB. Leukoencephalopathy complicating intraventricular catheters: clinical, radiographic and pathologic study of 10 cases. J Neurooncol 1988;6(1):67–74.

    Article  PubMed  CAS  Google Scholar 

  117. Valik D, Sterba J, Bajciova V et al. Severe encephalopathy induced by the first but not the second course of high-dose methotrexate mirrored by plasma homocysteine elevations and preceded by extreme differences in pretreatment plasma folate. Oncology 2005;69(3):269–272.

    Article  PubMed  CAS  Google Scholar 

  118. Winick NJ, Bowman WP, Kamen BA et al. Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia. J Natl Cancer Inst 1992;84(4):252–256.

    Article  PubMed  CAS  Google Scholar 

  119. Kuker W, Bader P, Herrlinger U et al. Transient encephalopathy after intrathekal methotrexate chemotherapy: diffusion-weighted MRI. J Neurooncol 2005;73(1):47–49.

    Article  PubMed  CAS  Google Scholar 

  120. Kinirons P, Fortune A, Enright H et al. Acute pseudobulbar palsy due to methotrexate with rapid response to intravenous immunoglobulin. J Neurol 2005;252(11):1401–1403.

    Article  PubMed  CAS  Google Scholar 

  121. Yim YS, Mahoney DH, Jr., Oshman DG. Hemiparesis and ischemic changes of the white matter after intrathecal therapy for children with acute lymphocytic leukemia. Cancer 1991;67(8):2058–2061.

    Article  PubMed  CAS  Google Scholar 

  122. Haykin ME, Gorman M, van Hoff J et al. Diffusion-weighted MRI correlates of subacute methotrexate-related neurotoxicity. J Neurooncol 2006;76(2):153–157.

    CAS  Google Scholar 

  123. Koh S, Nelson MD, Jr., Kovanlikaya A et al. Anterior lumbosacral radiculopathy after intrathecal methotrexate treatment. Pediatr Neurol 1999;21(2):576–578.

    Article  PubMed  CAS  Google Scholar 

  124. Dietrich J, Wen PY. Complications of chemotherapy. MedLink 2007.

    Google Scholar 

  125. Adamson PC, Balis FM, McCully CL et al. Rescue of experimental intrathecal methotrexate overdose with carboxypeptidase-G2. J Clin Oncol 1991;9(4):670–674.

    PubMed  CAS  Google Scholar 

  126. Ziereisen F, Dan B, Azzi N et al. Reversible acute methotrexate leukoencephalopathy: atypical brain MR imaging features. Pediatr Radiol 2006;36(3):205–212.

    Article  PubMed  Google Scholar 

  127. Fisher MJ, Khademian ZP, Simon EM et al. Diffusion-weighted MR imaging of early methotrexate-related neurotoxicity in children. AJNR Am J Neuroradiol 2005;26(7):1686–1689.

    PubMed  Google Scholar 

  128. Rollins N, Winick N, Bash R et al. Acute methotrexate neurotoxicity: findings on diffusion-weighted imaging and correlation with clinical outcome. AJNR Am J Neuroradiol 2004;25(10):1688–1695.

    PubMed  Google Scholar 

  129. Ettinger LJ, Freeman AI, Creaven PJ. Intrathecal methotrexate overdose without neurotoxicity: case report and literature review. Cancer 1978;41(4):1270–1273.

    Article  PubMed  CAS  Google Scholar 

  130. Widemann BC, Balis FM, Shalabi A et al. Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2. J Natl Cancer Inst 2004;96(20):1557–1559.

    Article  PubMed  CAS  Google Scholar 

  131. Finkelstein Y, Zevin S, Heyd J et al. Emergency treatment of life-threatening intrathecal methotrexate overdose. Neurotoxicology 2004;25(3):407–410.

    Article  PubMed  Google Scholar 

  132. Jakobson AM, Kreuger A, Mortimer O et al. Cerebrospinal fluid exchange after intrathecal methotrexate overdose: a report of two cases. Acta Paediatr 1992;81(4):359–361.

    Article  PubMed  CAS  Google Scholar 

  133. Spiegel RJ, Cooper PR, Blum RH et al. Treatment of massive intrathecal methotrexate overdose by ventriculolumbar perfusion. N Engl J Med 1984;311(6):386–368.

    PubMed  CAS  Google Scholar 

  134. Drachtman RA, Cole PD, Golden CB et al. Dextromethorphan is effective in the treatment of subacute methotrexate neurotoxicity. Pediatr Hematol Oncol 2002;19(5):319–327.

    Article  PubMed  CAS  Google Scholar 

  135. Wernick R, Smith DL. Central nervous system toxicity associated with weekly low-dose methotrexate treatment. Arthritis Rheum 1989;32(6):770–775.

    Article  PubMed  CAS  Google Scholar 

  136. Aplin CG, Russell-Jones R. Acute dysarthria induced by low-dose methotrexate therapy in a patient with erythrodermic cutaneous T-cell lymphoma: an unusual manifestation of neurotoxicity. Clin Exp Dermatol 1999;24(1):23–24.

    Article  PubMed  CAS  Google Scholar 

  137. Renard D, Westhovens R, Vandenbussche E et al. Reversible posterior leucoencephalopathy during oral treatment with methotrexate. J Neurol 2004;251(2):226–228.

    Article  PubMed  Google Scholar 

  138. Rubnitz JE, Relling MV, Harrison PL et al. Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphoblastic leukemia. Leukemia 1998;12(8):1176–1181.

    Article  PubMed  CAS  Google Scholar 

  139. Sanchez-Carpintero R, Narbona J, Lopez de Mesa R et al. Transient posterior encephalopathy induced by chemotherapy in children. Pediatr Neurol 2001;24(2):145–148.

    Article  PubMed  CAS  Google Scholar 

  140. Martino RL, Benson AB, 3rd, Merritt JA et al. Transient neurologic dysfunction following moderate-dose methotrexate for undifferentiated lymphoma. Cancer 1984;54(9):2003–2005.

    Article  PubMed  CAS  Google Scholar 

  141. Walker RW, Allen JC, Rosen G et al. Transient cerebral dysfunction secondary to high-dose methotrexate. J Clin Oncol 1986;4(12):1845–1850.

    PubMed  CAS  Google Scholar 

  142. Borgna-Pignatti C, Battisti L, Marradi P et al. Transient neurologic disturbances in a child treated with moderate-dose methotrexate. Br J Haematol 1992;81(3):448.

    Article  PubMed  CAS  Google Scholar 

  143. Phillips PC, Dhawan V, Strother SC et al. Reduced cerebral glucose metabolism and increased brain capillary permeability following high-dose methotrexate chemotherapy: a positron emission tomographic study. Ann Neurol 1987;21(1):59–63.

    Article  PubMed  CAS  Google Scholar 

  144. Millot F, Dhondt JL, Hayte JM et al. Impairment of cerebral biogenic amine synthesis in a patient receiving high-dose methotrexate. Am J Pediatr Hematol Oncol 1992;14(3):276–278.

    PubMed  CAS  Google Scholar 

  145. Rubinstein LJ, Herman MM, Long TF et al. Disseminated necrotizing leukoencephalopathy: a complication of treated central nervous system leukemia and lymphoma. Cancer 1975;35(2):291–305.

    Article  PubMed  CAS  Google Scholar 

  146. Pizzo PA, Poplack DG, Bleyer WA. Neurotoxicities of current leukemia therapy. Am J Pediatr Hematol Oncol 1979;1(2):127–140.

    PubMed  CAS  Google Scholar 

  147. Lovblad K, Kelkar P, Ozdoba C et al. Pure methotrexate encephalopathy presenting with seizures: CT and MRI features. Pediatr Radiol 1998;28(2):86–91.

    Article  PubMed  CAS  Google Scholar 

  148. Shuper A, Stark B, Kornreich L et al. Methotrexate-related neurotoxicity in the treatment of childhood acute lymphoblastic leukemia. Isr Med Assoc J 2002;4(11):1050–1053.

    PubMed  CAS  Google Scholar 

  149. Montour-Proulx I, Kuehn SM, Keene DL et al. Cognitive changes in children treated for acute lymphoblastic leukemia with chemotherapy only according to the Pediatric Oncology Group 9605 protocol. J Child Neurol 2005;20(2):129–133.

    Article  PubMed  Google Scholar 

  150. Ch’ien LT, Aur RJ, Verzosa M. S et al. Progression of methotrexate-induced leukoencephalopathy in children with leukemia. Med Pediatr Oncol 1981;9(2):133–141.

    Article  PubMed  CAS  Google Scholar 

  151. Ochs J, Mulhern R, Fairclough D et al. Comparison of neuropsychologic functioning and clinical indicators of neurotoxicity in long-term survivors of childhood leukemia given cranial radiation or parenteral methotrexate: a prospective study. J Clin Oncol 1991;9(1):145–151.

    PubMed  CAS  Google Scholar 

  152. Oka M, Terae S, Kobayashi R et al. MRI in methotrexate-related leukoencephalopathy: disseminated necrotising leukoencephalopathy in comparison with mild leukoencephalopathy. Neuroradiology 2003;45(7):493–497.

    Article  PubMed  CAS  Google Scholar 

  153. Laxmi SN, Takahashi S, Matsumoto K et al. Treatment-related disseminated necrotizing leukoencephalopathy with characteristic contrast enhancement of the white matter. Radiat Med 1996;14(6):303–307.

    PubMed  CAS  Google Scholar 

  154. Fernandez-Bouzas A, Ramirez Jimenez H, Vazquez Zamudio J et al. Brain calcifications and dementia in children treated with radiotherapy and intrathecal methotrexate. J Neurosurg Sci 1992;36(4):211–214.

    PubMed  CAS  Google Scholar 

  155. Hertzberg H, Huk WJ, Ueberall MA et al. CNS late effects after ALL therapy in childhood. Part I: Neuroradiological findings in long-term survivors of childhood ALL: an evaluation of the interferences between morphology and neuropsychological performance. The German Late Effects Working Group. Med Pediatr Oncol 1997;28(6):387–400.

    Article  PubMed  CAS  Google Scholar 

  156. Gangji D, Reaman GH, Cohen SR et al. Leukoencephalopathy and elevated levels of myelin basic protein in the cerebrospinal fluid of patients with acute lymphoblastic leukemia. N Engl J Med 1980;303(1):19–21.

    PubMed  CAS  Google Scholar 

  157. Lai R, Abrey LE, Rosenblum MK et al. Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study. Neurology 2004;62(3):451–456.

    PubMed  Google Scholar 

  158. Sakamaki H, Onozawa Y, Yano Y et al. Disseminated necrotizing leukoencephalopathy following irradiation and methotrexate therapy for central nervous system infiltration of leukemia and lymphoma. Radiat Med 1993;11(4):146–153.

    PubMed  CAS  Google Scholar 

  159. Price RA, Birdwell DA. The central nervous system in childhood leukemia. III. Mineralizing microangiopathy and dystrophic calcification. Cancer 1978;42(2):717–728.

    Article  PubMed  CAS  Google Scholar 

  160. Davidson A, Payne G, Leach MO et al. Proton magnetic resonance spectroscopy ((1)H-MRS) of the brain following high-dose methotrexate treatment for childhood cancer. Med Pediatr Oncol 2000;35(1):28–34.

    Article  PubMed  CAS  Google Scholar 

  161. Vezmar S, Becker A, Bode U, Jaehde U. Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy 2003;49(1–2):92–104.

    Google Scholar 

  162. Quinn CT, Griener JC, Bottiglieri T et al. Effects of intraventricular methotrexate on folate, adenosine, and homocysteine metabolism in cerebrospinal fluid. J Pediatr Hematol Oncol 2004;26(6):386–388.

    Article  PubMed  Google Scholar 

  163. Quinn CT, Griener JC, Bottiglieri T et al. Elevation of homocysteine and excitatory amino acid neurotransmitters in the CSF of children who receive methotrexate for the treatment of cancer. J Clin Oncol 1997;15(8):2800–2806.

    PubMed  CAS  Google Scholar 

  164. Miyatake S, Kikuchi H, Oda Y et al. A case of treatment-related leukoencephalopathy: sequential MRI, CT and PET findings. J Neurooncol 1992;14(2):143–149.

    Article  PubMed  CAS  Google Scholar 

  165. Linnebank M, Pels H, Kleczar N et al. MTX-induced white matter changes are associated with polymorphisms of methionine metabolism. Neurology 2005;64(5):912–913.

    PubMed  CAS  Google Scholar 

  166. Stordal B, Pavlakis N, Davey R. Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review. Cancer Treat Rev 2007;33(8):688–703.

    Article  PubMed  CAS  Google Scholar 

  167. Extra JM, Marty M, Brienza S et al. Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 1998;25(2 Suppl 5):13–22.

    PubMed  CAS  Google Scholar 

  168. Giacchetti S, Perpoint B, Zidani R et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil–leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18(1):136–147.

    PubMed  CAS  Google Scholar 

  169. Krishnan AV, Goldstein D, Friedlander M et al. Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve 2005;32(1):51–60.

    Article  PubMed  CAS  Google Scholar 

  170. Kiernan MC, Krishnan AV. The pathophysiology of oxaliplatin-induced neurotoxicity. Curr Med Chem 2006;13(24):2901–2907.

    Article  PubMed  CAS  Google Scholar 

  171. Cersosimo RJ. Oxaliplatin-associated neuropathy: a review. Ann Pharmacother 2005;39(1):128–135.

    PubMed  CAS  Google Scholar 

  172. Gamelin L, Boisdron-Celle M, Delva R et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 2004;10(12 Pt 1):4055–4061.

    Article  PubMed  CAS  Google Scholar 

  173. Hochster HS, Grothey A, Childs BH. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol 2007;25(25):4208–4209.

    Article  Google Scholar 

  174. Pasetto LM, D’Andrea MR, Rossi E et al. Oxaliplatin-related neurotoxicity: how and why? Crit Rev Oncol Hematol 2006;59(2):159–168.

    Article  PubMed  Google Scholar 

  175. Lersch C, Schmelz R, Eckel F et al. Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer. Clin Colorectal Cancer 2002;2(1):54–58.

    PubMed  CAS  Google Scholar 

  176. Penz M, Kornek GV, Raderer M et al. Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy. Ann Oncol 2001;12(3):421–422.

    Article  PubMed  CAS  Google Scholar 

  177. Argyriou AA, Chroni E, Polychronopoulos P et al. Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy. Neurology 2006;67(12):2253–2255.

    Article  PubMed  CAS  Google Scholar 

  178. Cassidy J, Bjarnason GA, Hickish T et al. Randomized double-blind placebo-controlled phase III study assessing the efficacy of xaliproden in reduicng the cumulative peripheral sensory neuropathy induced by the oxaliplatin and 5-FU/LV combination (FOLFOX4) in first-line treatment of patients with metastatic colorectal cancer. J Clin Oncol 2006;24:147s.

    Google Scholar 

  179. Cascinu S, Catalano V, Cordella L et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2002;20(16):3478–3483.

    Article  PubMed  CAS  Google Scholar 

  180. Wang WS, Lin JK, Lin TC et al. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. Oncologist 2007;12(3):312–319.

    Article  PubMed  CAS  Google Scholar 

  181. O’Dea D, Handy CM, Wexler A. Ocular changes with oxaliplatin. Clin J Oncol Nurs 2006;10(2):227–229.

    Article  PubMed  Google Scholar 

  182. Leonard GD, Wright MA, Quinn MG et al. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer 2005;5:116.

    Article  PubMed  CAS  Google Scholar 

  183. Skelton MR, Goldberg RM, O’Neil BH. A case of oxaliplatin-related posterior reversible encephalopathy syndrome. Clin Colorectal Cancer 2007;6(5):386–388.

    PubMed  CAS  Google Scholar 

  184. Moris G, Ribacoba R, Gonzalez C. Delayed posterior encephalopathy syndrome following chemotherapy with oxaliplatin and gemcitabine. J Neurol 2007.

    Google Scholar 

  185. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 1990;82(15):1247–1259.

    Article  PubMed  CAS  Google Scholar 

  186. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995;332(15):1004–1014.

    Google Scholar 

  187. Choy H, Rodriguez FF, Koester S et al. Investigation of taxol as a potential radiation sensitizer. Cancer 1993;71(11):3774–3778.

    Article  PubMed  CAS  Google Scholar 

  188. Postma TJ, Vermorken JB, Liefting AJ et al. Paclitaxel-induced neuropathy. Ann Oncol 1995;6(5):489–94.

    PubMed  CAS  Google Scholar 

  189. Lipton RB, Apfel SC, Dutcher JP et al. Taxol produces a predominantly sensory neuropathy. Neurology 1989;39(3):368–373.

    PubMed  CAS  Google Scholar 

  190. Freilich RJ, Balmaceda C, Seidman AD et al. Motor neuropathy due to docetaxel and paclitaxel. Neurology 1996;47(1):115–118.

    PubMed  CAS  Google Scholar 

  191. New PZ, Jackson CE, Rinaldi D et al. Peripheral neuropathy secondary to docetaxel (Taxotere). Neurology 1996;46(1):108–111.

    PubMed  CAS  Google Scholar 

  192. Rowinsky EK, Chaudhry V, Cornblath DR et al. Neurotoxicity of Taxol. J Natl Cancer Inst Monogr 1993(15):107–115.

    Google Scholar 

  193. Capri G, Munzone E, Tarenzi E et al. Optic nerve disturbances: a new form of paclitaxel neurotoxicity. J Natl Cancer Inst 1994;86(14):1099–1101.

    Article  PubMed  CAS  Google Scholar 

  194. Chang SM, Kuhn JG, Rizzo J et al. Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J Clin Oncol 1998;16(6):2188–2194.

    PubMed  CAS  Google Scholar 

  195. Brown T, Havlin K, Weiss G et al. A phase I trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol 1991;9(7):1261–1267.

    PubMed  CAS  Google Scholar 

  196. McGuire WP, Rowinsky EK, Rosenshein NB et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989;111(4):273–279.

    PubMed  CAS  Google Scholar 

  197. Perry JR, Warner, E. Transient encephalopathy after paclitaxel (Taxol) infusion. Neurology 1996;46(6):1596–1599.

    PubMed  CAS  Google Scholar 

  198. Guglani S, Farrugia D, Elsdon M et al. Reversible life-threatening encephalopathy in the absence of hepatic failure following conventional doses of docetaxel. Clin Oncol (R Coll Radiol) 2003;15(3):160–161.

    CAS  Google Scholar 

  199. Ziske CG, Schottker B, Gorschluter M et al. Acute transient encephalopathy after paclitaxel infusion: report of three cases. Ann Oncol 2002;13(4):629–631.

    Article  PubMed  CAS  Google Scholar 

  200. van den Bent MJ, Hilkens PH, Sillevis Smitt PA et al. Lhermitte’s sign following chemotherapy with docetaxel. Neurology 1998;50(2):563–564.

    PubMed  Google Scholar 

  201. Khattab J, Terebelo HR, Dabas, B. Phantom limb pain as a manifestation of paclitaxel neurotoxicity. Mayo Clin Proc 2000;75(7):740–742.

    PubMed  CAS  Google Scholar 

  202. Nieto Y, Cagnoni PJ, Bearman SI et al. Acute encephalopathy: a new toxicity associated with high-dose paclitaxel. Clin Cancer Res 1999;5(3):501–506.

    PubMed  CAS  Google Scholar 

  203. Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341(21):1565–1571.

    Article  PubMed  CAS  Google Scholar 

  204. Fine HA, Figg WD, Jaeckle K et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000;18(4):708–715.

    PubMed  CAS  Google Scholar 

  205. Little RF, Wyvill KM, Pluda JM et al. Activity of thalidomide in AIDS-related Kaposi’s sarcoma. J Clin Oncol 2000;18(13):2593–2602.

    PubMed  CAS  Google Scholar 

  206. Baidas SM, Winer EP, Fleming GF et al. Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Clin Oncol 2000;18(14):2710–2707.

    PubMed  CAS  Google Scholar 

  207. Chaudhry V, Cornblath DR, Corse A et al. Thalidomide-induced neuropathy. Neurology 2002;59(12):1872–1875.

    PubMed  CAS  Google Scholar 

  208. Bradley WG, Lassman LP, Pearce GW et al. The neuromyopathy of vincristine in man: clinical, electrophysiological, and pathological studies. J Neurol Sci 1970;10(2):107–131.

    Article  PubMed  CAS  Google Scholar 

  209. Moudgil SS, Riggs JE. Fulminant peripheral neuropathy with severe quadriparesis associated with vincristine therapy. Ann Pharmacother 2000;34(10):1136–1138.

    Article  PubMed  CAS  Google Scholar 

  210. Munier F, Perentes E, Herbort CP et al. Selective loss of optic nerve beta-tubulin in vincristine-induced blindness. Am J Med 1992;93(2):232–234.

    Article  PubMed  CAS  Google Scholar 

  211. Bain PG, Lantos PL, Djurovic V et al. Intrathecal vincristine: a fatal chemotherapeutic error with devastating central nervous system effects. J Neurol 1991;238(4):230–234.

    Article  PubMed  CAS  Google Scholar 

  212. Bleck TP, Jacobsen J. Prolonged survival following the inadvertent intrathecal administration of vincristine: clinical and electrophysiologic analyses. Clin Neuropharmacol 1991;14(5):457–462.

    Article  PubMed  CAS  Google Scholar 

  213. Hurwitz RL, Mahoney DH, Jr., Armstrong DL et al. Reversible encephalopathy and seizures as a result of conventional vincristine administration. Med Pediatr Oncol 1988;16(3):216–219.

    Article  PubMed  CAS  Google Scholar 

  214. Williams ME, Walker AN, Bracikowski JP et al. Ascending myeloencephalopathy due to intrathecal vincristine sulfate: a fatal chemotherapeutic error. Cancer 1983;51(11):2041–2047.

    Article  PubMed  CAS  Google Scholar 

  215. Qweider M, Gilsbach JM, Rohde V. Inadvertent intrathecal vincristine administration: a neurosurgical emergency: case report. J Neurosurg Spine 2007;6(3):280–283.

    Article  PubMed  Google Scholar 

  216. Byrd RL, Rohrbaugh TM, Raney RB, Jr. et al. Transient cortical blindness secondary to vincristine therapy in childhood malignancies. Cancer 1981;47(1):37–40.

    Article  PubMed  CAS  Google Scholar 

  217. Haefner MD, Siciliano RD, Widmer LA et al. Reversible posterior leukoencephalopathy syndrome after treatment of diffuse large B-cell lymphoma. Onkologie 2007;30(3):138–140.

    Article  PubMed  Google Scholar 

  218. Ozyurek H, Oguz G. Ozen, S et al. Reversible posterior leukoencephalopathy syndrome: report of three cases. J Child Neurol 2005;20(12):990–993.

    Google Scholar 

  219. Riehl JL, Brown WJ. Acute cerebellar syndrome secondary to 5-fluorouracil therapy. Neurology 1964;14:961–967.

    PubMed  CAS  Google Scholar 

  220. Boileau G, Piro AJ, Lahiri SR et al. Cerebellar ataxia during 5-fluorouracil (NSC-19893) therapy. Cancer Chemother Rep 1971;55(5):595–598.

    PubMed  CAS  Google Scholar 

  221. Greenwald ES. Letter: Organic mental changes with fluorouracil therapy. JAMA 1976;235(3):248–249.

    Article  PubMed  CAS  Google Scholar 

  222. Lynch HT, Droszcz CP, Albano WA et al. “Organic brain syndrome” secondary to 5-fluorouracil toxicity. Dis Colon Rectum 1981;24(2):130–131.

    Article  PubMed  CAS  Google Scholar 

  223. Liaw CC, Wang HM, Wang CH et al. Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection. Anticancer Drugs 1999;10(3):275–281.

    Article  PubMed  CAS  Google Scholar 

  224. Adams JW, Bofenkamp TM, Kobrin J et al. Recurrent acute toxic optic neuropathy secondary to 5-FU. Cancer Treat Rep 1984;68(3):565–566.

    PubMed  CAS  Google Scholar 

  225. Bixenman WW, Nicholls JV, Warwick OH. Oculomotor disturbances associated with 5-fluorouracil chemotherapy. Am J Ophthalmol 1977;83(6):789–793.

    PubMed  CAS  Google Scholar 

  226. Gradishar W, Vokes E, Schilsky R et al. Vascular events in patients receiving high-dose infusional 5-fluorouracil–based chemotherapy: the University of Chicago experience. Med Pediatr Oncol 1991;19(1):8–15.

    Article  Google Scholar 

  227. Brashear A, Siemers E. Focal dystonia after chemotherapy: a case series. J Neurooncol 1997;34(2):163–167.

    Article  PubMed  CAS  Google Scholar 

  228. Pirzada NA, Ali II, Dafer, RM. Fluorouracil-induced neurotoxicity. Ann Pharmacother 2000;34(1):35–38.

    Article  PubMed  CAS  Google Scholar 

  229. Takimoto CH, Lu ZH, Zhang R et al. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res 1996;2(3):477–481.

    PubMed  CAS  Google Scholar 

  230. Ohara S, Hayashi R, Hata S et al. Leukoencephalopathy induced by chemotherapy with tegafur, a 5-fluorouracil derivative. Acta Neuropathol (Berl) 1998;96(5):527–531.

    Article  CAS  Google Scholar 

  231. Hook CC, Kimmel DW, Kvols LK et al. Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole. Ann Neurol 1992;31(3):262–267.

    Article  PubMed  CAS  Google Scholar 

  232. Kimmel DW, Schutt AJ. Multifocal leukoencephalopathy: occurrence during 5-fluorouracil and levamisole therapy and resolution after discontinuation of chemotherapy. Mayo Clin Proc 1993;68(4):363–365.

    PubMed  CAS  Google Scholar 

  233. Savarese DM, Gordon J, Smith TW et al. Cerebral demyelination syndrome in a patient treated with 5-fluorouracil and levamisole: the use of thallium SPECT imaging to assist in noninvasive diagnosis: a case report. Cancer 1996;77(2):387–394.

    Article  PubMed  CAS  Google Scholar 

  234. Israel ZH, Lossos A, Barak V et al. Multifocal demyelinative leukoencephalopathy associated with 5-fluorouracil and levamisole. Acta Oncol 2000;39(1):117–120.

    Article  PubMed  CAS  Google Scholar 

  235. Chen TC, Hinton DR, Leichman L et al. Multifocal inflammatory leukoencephalopathy associated with levamisole and 5-fluorouracil: case report. Neurosurgery 1994;35(6):1138–1142;discussion 42–43.

    Article  PubMed  CAS  Google Scholar 

  236. Niemann B, Rochlitz C, Herrmann R et al. Toxic encephalopathy induced by capecitabine. Oncology 2004;66(4):331–335.

    Article  PubMed  CAS  Google Scholar 

  237. Videnovic A, Semenov I, Chua-Adajar R et al. Capecitabine-induced multifocal leukoencephalopathy: a report of five cases. Neurology 2005;65(11):1792–1794;discussion 685.

    Article  PubMed  CAS  Google Scholar 

  238. Haskell CM, Canellos GP, Leventhal BG et al. l-asparaginase: therapeutic and toxic effects in patients with neoplastic disease. N Engl J Med 1969;281(19):1028–1034.

    PubMed  CAS  Google Scholar 

  239. Haskell CM, Canellos GP, Leventhal BG et al. H. l-asparaginase toxicity. Cancer Res 1969;29(4):974–975.

    PubMed  CAS  Google Scholar 

  240. Leonard JV, Kay JD. Acute encephalopathy and hyperammonaemia complicating treatment of acute lymphoblastic leukaemia with asparaginase. Lancet 1986;1(8473):162–163.

    Article  PubMed  CAS  Google Scholar 

  241. Moure JM, Whitecar JP, Jr., Bodey GP. Electroencephalogram changes secondary to asparaginase. Arch Neurol 1970;23(4):365–368.

    PubMed  CAS  Google Scholar 

  242. Foreman NK, Mahmoud HH, Rivera GK et al. Recurrent cerebrovascular accident with l-asparaginase rechallenge. Med Pediatr Oncol 1992;20(6):532–534.

    Article  PubMed  CAS  Google Scholar 

  243. Ott N, Ramsay NK, Priest JR et al. Sequelae of thrombotic or hemorrhagic complications following l-asparaginase therapy for childhood lymphoblastic leukemia. Am J Pediatr Hematol Oncol 1988;10(3):191–195.

    PubMed  CAS  Google Scholar 

  244. Cairo MS, Lazarus K, Gilmore RL et al. Intracranial hemorrhage and focal seizures secondary to use of l-asparaginase during induction therapy of acute lymphocytic leukemia. J Pediatr 1980;97(5):829–833.

    Article  PubMed  CAS  Google Scholar 

  245. Priest JR, Ramsay NK, Steinherz PG et al. A syndrome of thrombosis and hemorrhage complicating l-asparaginase therapy for childhood acute lymphoblastic leukemia. J Pediatr 1982;100(6):984–989.

    Article  PubMed  CAS  Google Scholar 

  246. Schick RM, Jolesz F, Barnes PD et al. MR diagnosis of dural venous sinus thrombosis complicating l-asparaginase therapy. Comput Med Imaging Graph 1989;13(4):319–327.

    Article  PubMed  CAS  Google Scholar 

  247. Lee AY, Levine MN. The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost 1999;25(2):137–145.

    PubMed  CAS  Google Scholar 

  248. Hamdan MY, Frenkel EP, Bick R. l-asparaginase-provoked seizures as singular expression of central nervous toxicity. Clin Appl Thromb Hemost 2000;6(4):234–238.

    Article  PubMed  CAS  Google Scholar 

  249. Paleologos N. Complications of chemotherapy. In: Biller J (ed). Iatrogenic Neurology. Boston: Butterworth-Heinemann; 1998:439–460.

    Google Scholar 

  250. Cheson BD, Vena DA, Foss FM et al. Neurotoxicity of purine analogs: a review. J Clin Oncol 1994;12(10):2216–2228.

    PubMed  CAS  Google Scholar 

  251. Ignoffo RJ, Viele CS, Damon LE et al. Cancer Chemotherapy Pocket Guide. Philadelphia: Lippincott-Raven; 1998.

    Google Scholar 

  252. Schachter S, Freeman R. Transient ischemic attack and adriamycin cardiomyopathy. Neurology 1982;32(12):1380–1381.

    PubMed  CAS  Google Scholar 

  253. Arico M, Nespoli L, Porta F et al. Severe acute encephalopathy following inadvertent intrathecal doxorubicin administration. Med Pediatr Oncol 1990;18(3):261–263.

    Article  PubMed  CAS  Google Scholar 

  254. Neuwelt EA, Pagel M, Barnett P et al. Pharmacology and toxicity of intracarotid adriamycin administration following osmotic blood–brain barrier modification. Cancer Res 1981;41(11 Pt 1):4466–4470.

    PubMed  CAS  Google Scholar 

  255. Barbui T, Rambaldi A, Parenzan L et al. Neurological symptoms and coma associated with doxorubicin administration during chronic cyclosporin therapy. Lancet 1992;339(8806):1421.

    Article  PubMed  CAS  Google Scholar 

  256. Hall C, Dougherty WJ, Lebish IJ et al. Warning against use of intrathecal mitoxantrone. Lancet 1989;1(8640):734.

    Article  PubMed  CAS  Google Scholar 

  257. Lakhani AK, Zuiable AG, Pollard CM et al. Paraplegia after intrathecal mitozantrone. Lancet 1986;2(8520):1393.

    Article  PubMed  CAS  Google Scholar 

  258. Wilhelm M, O’Brien S, Rios MB et al. Phase I study of arabinosyl-5-azacytidine (fazarabine) in adult acute leukemia and chronic myelogenous leukemia in blastic phase. Leuk Lymphoma 1999;34(5–6):511–518.

    PubMed  CAS  Google Scholar 

  259. Doll DC, Yarbro JW. Vascular toxicity associated with antineoplastic agents. Semin Oncol 1992;19(5):580–596.

    PubMed  CAS  Google Scholar 

  260. Vogelzang NJ. Vascular and other complications of chemotherapy for testicular cancer. Worl J Urol 1984;2:32–37.

    Article  Google Scholar 

  261. Vassal G, Deroussent A, Hartmann O et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res 1990;50(19):6203–6207.

    PubMed  CAS  Google Scholar 

  262. Walker RW, Rosenblum MK, Kempin SJ et al. Carboplatin-associated thrombotic microangiopathic hemolytic anemia. Cancer 1989;64(5):1017–1020.

    Article  PubMed  CAS  Google Scholar 

  263. O’Brien ME, Tonge K, Blake P et al. Blindness associated with high-dose carboplatin. Lancet 1992;339(8792):558.

    Article  PubMed  CAS  Google Scholar 

  264. Stewart DJ, Belanger JM, Grahovac Z et al. Phase I study of intracarotid administration of carboplatin. Neurosurgery 1992;30(4):512–516; discussion 6–7.

    Article  PubMed  CAS  Google Scholar 

  265. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol 2002;249(1):9–17.

    Article  PubMed  CAS  Google Scholar 

  266. Alberts DS. Clinical pharmacology of carboplatin. Semin Oncol 1990;17(4 Suppl 7):6–8.

    PubMed  CAS  Google Scholar 

  267. Vandenberg SA, Kulig K, Spoerke DG et al. Chlorambucil overdose: accidental ingestion of an antineoplastic drug. J Emerg Med 1988;6(6):495–498.

    Article  PubMed  CAS  Google Scholar 

  268. Wyllie AR, Bayliff CD, Kovacs MJ. Myoclonus due to chlorambucil in two adults with lymphoma. Ann Pharmacother 1997;31(2):171–174.

    PubMed  CAS  Google Scholar 

  269. Blumenreich MS, Woodcock TM., Sherrill EJ et al. A phase I trial of chlorambucil administered in short pulses in patients with advanced malignancies. Cancer Invest 1988;6(4):371–375.

    Article  PubMed  CAS  Google Scholar 

  270. Salloum E, Khan KK, Cooper DL. Chlorambucil-induced seizures. Cancer 1997;79(5):1009–1013.

    Article  PubMed  CAS  Google Scholar 

  271. Burns LJ. Ocular toxicities of chemotherapy. Semin Oncol 1992;19(5):492–500.

    PubMed  CAS  Google Scholar 

  272. Chabner BA, Longo DL. Cancer Chemotherapy and Biotherapy: Principles and Practice. 2nd ed. Philadelphia: Lippincott-Raven; 1996.

    Google Scholar 

  273. Phillips PC, Than TT, Cork LC et al. Intrathecal 4-hydroperoxycyclophosphamide: neurotoxicity, cerebrospinal fluid pharmacokinetics, and antitumor activity in a rabbit model of VX2 leptomeningeal carcinomatosis. Cancer Res 1992;52(22):6168–6174.

    PubMed  CAS  Google Scholar 

  274. Paterson AH, McPherson, TA. A possible neurologic complication of DTIC. Cancer Treat Rep 1977;61(1):105–106.

    PubMed  CAS  Google Scholar 

  275. Lubiniecki GM, Berlin JA, Weinstein RB et al. Thromboembolic events with estramustine phosphate-based chemotherapy in patients with hormone-refractory prostate carcinoma: results of a meta-analysis. Cancer 2004;101(12):2755–2759.

    Article  PubMed  CAS  Google Scholar 

  276. Leff RS, Thompson JM, Daly MB et al. Acute neurologic dysfunction after high-dose etoposide therapy for malignant glioma. Cancer 1988;62(1):32–35.

    Article  PubMed  CAS  Google Scholar 

  277. Cohen RB, Abdallah JM, Gray JR et al. Reversible neurologic toxicity in patients treated with standard-dose fludarabine phosphate for mycosis fungoides and chronic lymphocytic leukemia. Ann Intern Med 1993;118(2):114–116.

    PubMed  CAS  Google Scholar 

  278. Spriggs DR, Stopa E, Mayer RJ et al. Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study. Cancer Res 1986;46(11):5953–5958.

    PubMed  CAS  Google Scholar 

  279. Chun HG, Leyland-Jones BR, Caryk SM et al. Central nervous system toxicity of fludarabine phosphate. Cancer Treat Rep 1986;70(10):1225–1228.

    PubMed  CAS  Google Scholar 

  280. Warrell RP, Jr., Berman E. Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J Clin Oncol 1986;4(1):74–79.

    PubMed  Google Scholar 

  281. Mielke S, Potthoff K, Feuerhake F et al. Fatal leukoencephalopathy after reduced-intensity allogeneic stem cell transplantation. Onkologie 2007;30(1–2):49–52.

    Article  PubMed  Google Scholar 

  282. Rodriguez L, Ribera JM, Batlle M et al. Progressive multifocal leukoencephalopathy shortly after the diagnosis of follicular lymphoma in a patient treated with fludarabine. Haematologica 2002;87(7):ECR26.

    PubMed  Google Scholar 

  283. Kiewe P, Seyfert S, Korper S et al. Progressive multifocal leukoencephalopathy with detection of JC virus in a patient with chronic lymphocytic leukemia parallel to onset of fludarabine therapy. Leuk Lymphoma 2003;44(10):1815–1818.

    Article  PubMed  Google Scholar 

  284. Saumoy M, Castells G, Escoda L et al. Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia after treatment with fludarabine. Leuk Lymphoma 2002;43(2):433–436.

    Article  PubMed  Google Scholar 

  285. Vidarsson B, Mosher F, Salamat MS et al. T. Progressive multifocal leukoencephalopathy after fludarabine therapy for low-grade lymphoproliferative disease. Am J Hematol 2002;70(1):51–54.

    Article  PubMed  Google Scholar 

  286. Cid J, Revilla M, Cervera A et al. Progressive multifocal leukoencephalopathy following oral fludarabine treatment of chronic lymphocytic leukemia. Ann Hematol 2000;79(7):392–395.

    Article  PubMed  CAS  Google Scholar 

  287. Gonzalez H, Bolgert F, Camporo P et al. Progressive multifocal leukoencephalitis (PML) in three patients treated with standard-dose fludarabine (FAMP). Hematol Cell Ther 1999;41(4):183–186.

    Article  PubMed  CAS  Google Scholar 

  288. Airoldi M, Cattel L, Passera R et al. Gemcitabine and oxaliplatin in patients with metastatic breast cancer resistant to or pretreated with both anthracyclines and taxanes: clinical and pharmacokinetic data. Am J Clin Oncol 2006;29(5):490–494.

    Article  PubMed  CAS  Google Scholar 

  289. Harder J, Riecken B, Kummer O et al. Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. Br J Cancer 2006;95(7):848–852.

    Article  PubMed  CAS  Google Scholar 

  290. Liu HM, Hsieh WJ, Yang CC et al. Leukoencephalopathy induced by levamisole alone for the treatment of recurrent aphthous ulcers. Neurology 2006;67(6):1065–1067.

    Article  PubMed  CAS  Google Scholar 

  291. Wu VC, Huang JW, Lien HC et al. Levamisole-induced multifocal inflammatory leukoencephalopathy: clinical characteristics, outcome, and impact of treatment in 31 patients. Medicine (Baltimore) 2006;85(4):203–213.

    Article  CAS  Google Scholar 

  292. Lin CH, Jeng JS, Hsieh ST. et al. Acute disseminated encephalomyelitis: a follow-up study in Taiwan. J Neurol Neurosurg Psychiatry 2007;78(2):162–167.

    Article  PubMed  Google Scholar 

  293. Sullivan KM, Storb R, Shulman HM et al. Immediate and delayed neurotoxicity after mechlorethamine preparation for bone marrow transplantation. Ann Intern Med 1982;97(2):182–189.

    PubMed  CAS  Google Scholar 

  294. Shapiro WR, Young DF. Neurological complications of antineoplastic therapy. Acta Neurol Scand Suppl 1984;100:125–132.

    PubMed  CAS  Google Scholar 

  295. Shapiro WR, Green SB. Reevaluating the efficacy of intra-arterial BCNU. J Neurosurg 1987;66(2):313–315.

    PubMed  CAS  Google Scholar 

  296. Shapiro WR, Green SB, Burger PC et al. A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg 1992;76(5):772–781.

    PubMed  CAS  Google Scholar 

  297. Bashir R, Hochberg FH, Linggood RM et al. Pre-irradiation internal carotid artery BCNU in treatment of glioblastoma multiforme. J Neurosurg 1988;68(6):917–919.

    PubMed  CAS  Google Scholar 

  298. Rosenblum MK, Delattre JY, Walker RW et al. Fatal necrotizing encephalopathy complicating treatment of malignant gliomas with intra-arterial BCNU and irradiation: a pathological study. J Neurooncol 1989;7(3):269–281.

    Article  PubMed  CAS  Google Scholar 

  299. Kleinschmidt-DeMasters BK, Geier JM. Pathology of high-dose intraarterial BCNU. Surg Neurol 1989;31(6):435–443.

    Article  PubMed  CAS  Google Scholar 

  300. Moore-Maxwell CA, Datto MB, Hulette CM. Chemotherapy-induced toxic leukoencephalopathy causes a wide range of symptoms: a series of four autopsies. Mod Pathol 2004;17(2):241–247.

    Article  PubMed  Google Scholar 

  301. Fung LK, Ewend MG, Sills A et al. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res 1998;58(4):672–684.

    PubMed  CAS  Google Scholar 

  302. Fleming AB, Saltzman WM. Pharmacokinetics of the carmustine implant. Clin Pharmacokinet 2002;41(6):403–419.

    Article  PubMed  CAS  Google Scholar 

  303. Duffner PK. The long-term effects of chemotherapy on the central nervous system. J Biol 2006;5(7):21.

    Article  PubMed  Google Scholar 

  304. Weiss HD, Walker MD, Wiernik PH. Neurotoxicity of commonly used antineoplastic agents (first of two parts). N Engl J Med 1974;291(2):75–81.

    PubMed  CAS  Google Scholar 

  305. Postma TJ, van Groeningen CJ, Witjes RJ et al. Neurotoxicity of combination chemotherapy with procarbazine, CCNU, and vincristine (PCV) for recurrent glioma. J Neurooncol 1998;38(1):69–75.

    Article  PubMed  CAS  Google Scholar 

  306. LoRusso P, Foster BJ, Poplin E et al. Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934). Clin Cancer Res 1995;1(12):1487–1493.

    PubMed  CAS  Google Scholar 

  307. Rowinsky EK, Noe DA, Grochow LB et al. Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules. J Clin Oncol 1995;13(8):1975–1984.

    PubMed  CAS  Google Scholar 

  308. Bailey J, Pluda JM, Foli A et al. Phase I/II study of intermittent all-trans-retinoic acid, alone and in combination with interferon alfa-2a, in patients with epidemic Kaposi’s sarcoma. J Clin Oncol 1995;13(8):1966–1974.

    PubMed  CAS  Google Scholar 

  309. Selleri C, Pane F, Notaro R et al. All-trans-retinoic acid (ATRA) responsive skin relapses of acute promyelocytic leukaemia followed by ATRA-induced pseudotumour cerebri. Br J Haematol 1996;92(4):937–940.

    Article  PubMed  CAS  Google Scholar 

  310. Smith MA, Adamson PC, Balis FM et al. Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer. J Clin Oncol 1992;10(11):1666–1673.

    PubMed  CAS  Google Scholar 

  311. Yamaji S, Kanamori H, Mishima A et al. All-trans retinoic acid-induced multiple mononeuropathies. Am J Hematol 1999;60(4):311.

    Article  PubMed  CAS  Google Scholar 

  312. Bigby M, Stern RS. Adverse reactions to isotretinoin: a report from the Adverse Drug Reaction Reporting System. J Am Acad Dermatol 1988;18(3):543–552.

    PubMed  CAS  Google Scholar 

  313. Maden M, Holder N. Retinoic acid and development of the central nervous system. Bioessays 1992;14(7):431–438.

    Article  PubMed  CAS  Google Scholar 

  314. Durston AJ, Timmermans JP, Hage WJ et al. Retinoic acid causes an anteroposterior transformation in the developing central nervous system. Nature 1989;340(6229):140–144.

    Article  PubMed  CAS  Google Scholar 

  315. Yamamoto M, Ullman D, Drager UC et al. Postnatal effects of retinoic acid on cerebellar development. Neurotoxicol Teratol 1999;21(2):141–146.

    Article  PubMed  CAS  Google Scholar 

  316. Chaudhry V, Eisenberger MA, Sinibaldi VJ et al. A prospective study of suramin-induced peripheral neuropathy. Brain 1996;119 (Pt 6):2039–2052.

    Article  PubMed  Google Scholar 

  317. La Rocca RV, Meer J, Gilliatt RW et al. Suramin-induced polyneuropathy. Neurology 1990;40(6):954–960.

    PubMed  Google Scholar 

  318. Kaur M, Reed E, Sartor O et al. Suramin’s development: what did we learn? Invest New Drugs 2002;20(2):209–219.

    Article  PubMed  CAS  Google Scholar 

  319. Hussain M, Fisher EI, Petrylak DP et al. Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: a Southwest Oncology Group Study. J Clin Oncol 2000;18(5):1043–1049.

    PubMed  CAS  Google Scholar 

  320. Yung WK, Prados MD, Yaya-Tur R et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 1999;17(9):2762–2771.

    PubMed  CAS  Google Scholar 

  321. Chamberlain MC, Tsao-Wei DD, Groshen S. Temozolomide for treatment-resistant recurrent meningioma. Neurology 2004;62(7):1210–1212.

    PubMed  CAS  Google Scholar 

  322. Tirelli U, Carbone A, Crivellari D et al. A phase II trial of teniposide (VM 26) in advanced non-Hodgkin’s lymphoma, with emphasis on the treatment of elderly patients. Cancer 1984;54(3):393–396.

    Article  PubMed  CAS  Google Scholar 

  323. Gutin PH, Levi JA, Wiernik PH et al. Treatment of malignant meningeal disease with intrathecal thioTEPA: a phase II study. Cancer Treat Rep 1977;61(5):885–887.

    PubMed  CAS  Google Scholar 

  324. Valteau-Couanet D, Fillipini B, Benhamou E et al. High-dose busulfan and thiotepa followed by autologous stem cell transplantation (ASCT) in previously irradiated medulloblastoma patients: high toxicity and lack of efficacy. Bone Marrow Transplant 2005;36(11):939–945.

    Article  PubMed  CAS  Google Scholar 

  325. Nemoto T, Rosner D, Patel JK et al. Aminoglutethimide in patients with metastatic breast cancer. Cancer 1989;63(9):1673–1675.

    Article  PubMed  CAS  Google Scholar 

  326. Wiseman LR, Adkins JC. Anastrozole: a review of its use in the management of post-menopausal women with advanced breast cancer. Drugs Aging 1998;13(4):321–332.

    Article  PubMed  CAS  Google Scholar 

  327. Vecht CJ, Verbiest HBC. Use of glucocorticoids in neuro-oncology. In: Dekker M, (ed.). Neurological Complications of Cancer. New York: Wiley; 1995:199–218.

    Google Scholar 

  328. Dropcho EJ, Soong SJ. Steroid-induced weakness in patients with primary brain tumors. Neurology 1991;41(8):1235–1239.

    PubMed  CAS  Google Scholar 

  329. Rosener M, Martin E, Zipp F et al. Neurologic side-effects of pharmacologic corticoid therapy. Nervenarzt 1996;67(12):983–986.

    Article  PubMed  CAS  Google Scholar 

  330. Stiefel FC, Breitbart WS, Holland JC. Corticosteroids in cancer: neuropsychiatric complications. Cancer Invest 1989;7(5):479–491.

    Article  PubMed  CAS  Google Scholar 

  331. Lewis DA, Smith RE. Steroid-induced psychiatric syndromes: a report of 14 cases and a review of the literature. J Affect Disord 1983;5(4):319–332.

    Article  PubMed  CAS  Google Scholar 

  332. Baethge BA, Lidsky MD. Intractable hiccups associated with high-dose intravenous methylprednisolone therapy. Ann Intern Med 1986;104(1):58–59.

    PubMed  CAS  Google Scholar 

  333. Haddad SF, Hitchon PW, Godersky JC. Idiopathic and glucocorticoid-induced spinal epidural lipomatosis. J Neurosurg 1991;74(1):38–42.

    PubMed  CAS  Google Scholar 

  334. Ernst G, Gericke A, Berg P. Central pain and complex motoric symptoms after gosarelin therapy of prostate cancer. Sci World J 2004;4:969–973.

    CAS  Google Scholar 

  335. Akaboshi S, Takeshita K. A case of atypical absence seizures induced by leuprolide acetate. Pediatr Neurol 2000;23(3):266–268.

    Article  PubMed  CAS  Google Scholar 

  336. Lanser JB, van Seters AP, Moolenaar AJ et al. Neuropsychologic and neurologic side effects of mitotane and reversibility of symptoms. J Clin Oncol 1992;10(9):1504.

    PubMed  CAS  Google Scholar 

  337. Kaiser-Kupfer MI, Lippman ME. Tamoxifen retinopathy. Cancer Treat Rep 1978;62(3):315–320.

    PubMed  CAS  Google Scholar 

  338. Nayfield SG, Gorin MB. Tamoxifen-associated eye disease: a review. J Clin Oncol 1996;14(3):1018–1026.

    PubMed  CAS  Google Scholar 

  339. Pavlidis NA, Petris C, Briassoulis E et al. Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity: a prospective study of 63 patients. Cancer 1992;69(12):2961–2964.

    Article  PubMed  CAS  Google Scholar 

  340. Ashford AR, Donev I, Tiwari RP et al. Reversible ocular toxicity related to tamoxifen therapy. Cancer 1988;61(1):33–35.

    Article  PubMed  CAS  Google Scholar 

  341. Ron IG, Inbar MJ, Barak Y et al. Organic delusional syndrome associated with tamoxifen treatment. Cancer 1992;69(6):1415–1417.

    Article  PubMed  CAS  Google Scholar 

  342. Pluss JL, DiBella NJ. Reversible central nervous system dysfunction due to tamoxifen in a patient with breast cancer. Ann Intern Med 1984;101(5):652.

    PubMed  CAS  Google Scholar 

  343. Chang SM, Barker FG, 2nd, Huhn SL et al. High-dose oral tamoxifen and subcutaneous interferon alpha-2a for recurrent glioma. J Neurooncol 1998;37(2):169–176.

    Article  PubMed  CAS  Google Scholar 

  344. Parry BR. Radiation recall induced by tamoxifen. Lancet 1992;340(8810):49.

    Article  PubMed  CAS  Google Scholar 

  345. Tang P, Roldan G, Brasher PM et al. A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma. J Neurooncol 2006;78(3):311–316.

    Article  PubMed  CAS  Google Scholar 

  346. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991;9(2):286–294.

    PubMed  CAS  Google Scholar 

  347. Gianni L, Panzini I, Li S et al. Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials. Cancer 2006;106(3):505–513.

    Article  PubMed  CAS  Google Scholar 

  348. Caraceni A, Gangeri L, Martini C et al. Neurotoxicity of interferon-alpha in melanoma therapy: results from a randomized controlled trial. Cancer 1998;83(3):482–489.

    Article  PubMed  CAS  Google Scholar 

  349. Meyers CA, Obbens EA, Scheibel RS et al. Neurotoxicity of intraventricularly administered alpha-interferon for leptomeningeal disease. Cancer 1991;68(1):88–92.

    Article  PubMed  CAS  Google Scholar 

  350. Meyers CA, Scheibel RS, Forman AD. Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 1991;41(5):672–676.

    PubMed  CAS  Google Scholar 

  351. Rohatiner AZ, Prior PF, Burton AC et al. Central nervous system toxicity of interferon. Br J Cancer 1983;47(3):419–422.

    PubMed  CAS  Google Scholar 

  352. Ulbricht D, Metz RJ, Ries F et al Alpha-interferon encephalopathy. Neurology 2003;61(9):1301.

    PubMed  Google Scholar 

  353. Spiegel RJ. The alpha interferons: clinical overview. Semin Oncol 1987;14(2 Suppl 2):1–12.

    PubMed  CAS  Google Scholar 

  354. Smedley H, Katrak M, Sikora K et al. Neurological effects of recombinant human interferon. Br Med J (Clin Res Ed) 1983;286(6361):262–264.

    CAS  Google Scholar 

  355. Amodio P, De Toni EN, Cavalletto L et al. Mood, cognition, and EEG changes during interferon alpha (alpha-IFN) treatment for chronic hepatitis C. J Affect Disord 2005;84(1):93–98.

    Article  PubMed  CAS  Google Scholar 

  356. Suter CC, Westmoreland BF, Sharbrough FW et al. Electroencephalographic abnormalities in interferon encephalopathy: a preliminary report. Mayo Clin Proc 1984;59(12):847–850.

    PubMed  CAS  Google Scholar 

  357. Nishihori T, Abdo-Matkiwsky M, Fleishman SB et al. Severe action tremor related to interferon-alpha 2b therapy for malignant melanoma. Am J Clin Oncol 2005;28(5):526.

    Article  PubMed  Google Scholar 

  358. Esmaeli B, Koller C, Papadopoulos N et al. Interferon-induced retinopathy in asymptomatic cancer patients. Ophthalmology 2001;108(5):858–860.

    Article  PubMed  CAS  Google Scholar 

  359. Hejny C, Sternberg P, Lawson DH et al. Retinopathy associated with high-dose interferon alfa-2b therapy. Am J Ophthalmol 2001;131(6):782–787.

    Article  PubMed  CAS  Google Scholar 

  360. Vesikari T, Nuutila A, Cantell K. Neurologic sequelae following interferon therapy of juvenile laryngeal papilloma. Acta Paediatr Scand 1988;77(4):619–622.

    Article  PubMed  CAS  Google Scholar 

  361. Hensley ML, Peterson B, Silver RT et al. Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013. J Clin Oncol 2000;18(6):1301–1308.

    PubMed  CAS  Google Scholar 

  362. Wichers MC, Koek GH, Robaeys G et al. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 2005;10(6):538–544.

    Article  PubMed  CAS  Google Scholar 

  363. Delattre JY, Vega F, Chen Q. Neurologic complications of immunotherapy. In: Dekker M, (ed.). Neurologic Complications of Cancer. New York: Wiley; 1995:267–293.

    Google Scholar 

  364. Denicoff KD, Durkin TM, Lotze MT et al. The neuroendocrine effects of interleukin-2 treatment. J Clin Endocrinol Metab 1989;69(2):402–410.

    PubMed  CAS  Google Scholar 

  365. Denicoff KD, Rubinow DR, Papa MZ et al. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 1987;107(3):293–300.

    PubMed  CAS  Google Scholar 

  366. Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol 1991;9(4):694–704.

    PubMed  CAS  Google Scholar 

  367. Bernard JT, Ameriso S, Kempf RA et al. Transient focal neurologic deficits complicating interleukin-2 therapy. Neurology 1990;40(1):154–155.

    PubMed  CAS  Google Scholar 

  368. Karp BI, Yang JC, Khorsand M et al. Multiple cerebral lesions complicating therapy with interleukin-2. Neurology 1996;47(2):417–424.

    PubMed  CAS  Google Scholar 

  369. Somers SS, Reynolds JV, Guillou PJ. Multifocal neurotoxicity during interleukin-2 therapy for malignant melanoma. Clin Oncol (R Coll Radiol) 1992;4(2):135–136.

    CAS  Google Scholar 

  370. Vecht CJ, Keohane C, Menon RS et al. Acute fatal leukoencephalopathy after interleukin-2 therapy. N Engl J Med 1990;323(16):1146–1147.

    PubMed  CAS  Google Scholar 

  371. Barba D, Saris SC, Holder C. et al. Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 1989;70(2):175–182.

    Article  PubMed  CAS  Google Scholar 

  372. Meyers CA, Yung WK. Delayed neurotoxicity of intraventricular interleukin-2: a case report. J Neuro-oncol 1993;15(3):265–267.

    Article  CAS  Google Scholar 

  373. Hotton KM, Khorsand M, Hank JA et al. A phase Ib/II trial of granulocyte-macrophage-colony stimulating factor and interleukin-2 for renal cell carcinoma patients with pulmonary metastases: a case of fatal central nervous system thrombosis. Cancer 2000;88(8):1892–1901.

    Article  PubMed  CAS  Google Scholar 

  374. Tulpule A, Joshi B, DeGuzman N et al. Interleukin-4 in the treatment of AIDS-related Kaposi’s sarcoma. Ann Oncol 1997;8(1):79–83.

    Article  PubMed  CAS  Google Scholar 

  375. Leniger T, Kastrup O, Diener HC. Reversible posterior leukencephalopathy syndrome induced by granulocyte stimulating factor filgrastim. J Neurol Neurosurg Psychiatry 2000;69(2):280–281.

    Article  PubMed  CAS  Google Scholar 

  376. Peterson DC, Inwards DJ, Younge BR. Oprelvekin-associated bilateral optic disk edema. Am J Ophthalmol 2005;139(2):367–368.

    Article  PubMed  Google Scholar 

  377. Grothey A. Recognizing and managing toxicities of molecular targeted therapies for colorectal cancer. Oncology (Williston Park) 2006;20(14 Suppl 10):21–28.

    Google Scholar 

  378. Motl S. Bevacizumab in combination chemotherapy for colorecal and other cancers. Am J Health Syst Pharm 2005;62(10):1021–1032.

    PubMed  CAS  Google Scholar 

  379. Zhu X, Wu S, Dahut WL et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007;49(2):186–193.

    Article  PubMed  CAS  Google Scholar 

  380. Shih T, Lindley, C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006;28(11):1779–1802.

    Article  PubMed  CAS  Google Scholar 

  381. Vredenburgh JJ, Desjardins A, Herndon JE, 2nd et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13(4):1253–1259.

    Article  PubMed  CAS  Google Scholar 

  382. Herbst RS. Toxicities of antiangiogenic therapy in non-small cell lung cancer. Clin Lung Cancer 2006;8 Suppl 1:S23–S30.

    PubMed  CAS  Google Scholar 

  383. Ozcan C, Wong SJ, Hari, P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006;354(9):980–982; discussion 982.

    Article  PubMed  Google Scholar 

  384. Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006;354(9):980–982; discussion 982.

    Article  PubMed  CAS  Google Scholar 

  385. Meyer CH, Mennel S, Horle S et al. Visual hallucinations after intravitreal injection of bevacizumab in vascular age-related macular degeneration. Am J Ophthalmol 2007;143(1):169–170.

    Article  PubMed  CAS  Google Scholar 

  386. Shah CP, Hsu J, Garg SJ et al. Retinal pigment epithelial tear after intravitreal bevacizumab injection. Am J Ophthalmol 2006;142(6):1070–1072.

    Article  PubMed  CAS  Google Scholar 

  387. Spandau UH, Jonas JB. Retinal pigment epithelium tear after intravitreal bevacizumab for exudative age-related macular degeneration. Am J Ophthalmol 2006;142(6):1068–1070.

    Article  PubMed  CAS  Google Scholar 

  388. Vanhoefer U, Tewes M, Rojo F et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 2004;22(1):175–184.

    Article  PubMed  CAS  Google Scholar 

  389. Wiseman GA, Leigh B, Erwin WD et al. Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma. Cancer 2002;94(4 Suppl):1349–1357.

    Article  PubMed  CAS  Google Scholar 

  390. Kaminski MS, Estes J, Zasadny KR et al. Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000;96(4):1259–1266.

    PubMed  CAS  Google Scholar 

  391. Vose JM, Wahl RL, Saleh M et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol 2000;18(6):1316–1323.

    PubMed  CAS  Google Scholar 

  392. Foran JM, Rohatiner AZ, Cunningham D et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle–cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000;18(2):317–324.

    PubMed  CAS  Google Scholar 

  393. Maloney DG, Grillo-Lopez AJ, Bodkin DJ et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin’s lymphoma. J Clin Oncol 1997;15(10):3266–3274.

    PubMed  CAS  Google Scholar 

  394. Maloney DG, Press OW. Newer treatments for non-Hodgkin’s lymphoma: monoclonal antibodies. Oncology (Williston Park) 1998;12(10 Suppl 8):63–76.

    CAS  Google Scholar 

  395. Steurer M, Clausen J, Gotwald T et al. Progressive multifocal leukoencephalopathy after allogeneic stem cell transplantation and posttransplantation rituximab. Transplantation 2003;76(2):435–436.

    Article  PubMed  Google Scholar 

  396. Matteucci P, Magni M, Di Nicola M et al. Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody. Blood 2002;100(3):1104–1105.

    Article  PubMed  Google Scholar 

  397. Goldberg SL, Pecora AL, Alter RS et al. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high–dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 2002;99(4):1486–1488.

    Article  PubMed  CAS  Google Scholar 

  398. Shak S. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin Oncol 1999;26(4 Suppl 12):71–77.

    PubMed  CAS  Google Scholar 

  399. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2–overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17(9):2639–2648.

    PubMed  CAS  Google Scholar 

  400. Baselga J, Carbonell X, Castaneda-Soto NJ et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005;23(10):2162–2171.

    Article  PubMed  CAS  Google Scholar 

  401. Richardson, PG, Briemberg H, Jagannath S et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006;24(19):3113–3120.

    Article  PubMed  CAS  Google Scholar 

  402. Herbst RS, Fukuoka M, Baselga, J. Gefitinib: a novel targeted approach to treating cancer. Nat Rev Cancer 2004;4(12):956–965.

    Article  PubMed  CAS  Google Scholar 

  403. Baselga J, Rischin D, Ranson M et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002;20(21):4292–4302.

    Article  PubMed  CAS  Google Scholar 

  404. Chau I, Cunningham D, Hickish T et al. Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I–II study. Ann Oncol 2007;18(4):730–737.

    Article  PubMed  CAS  Google Scholar 

  405. Druker BJ, Sawyers CL, Kantarjian H et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344(14):1038–1042.

    Article  PubMed  CAS  Google Scholar 

  406. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344(14):1031–1037.

    Article  PubMed  CAS  Google Scholar 

  407. Joensuu H, Roberts PJ, Sarlomo-Rikala M. et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344(14):1052–1056.

    Article  PubMed  CAS  Google Scholar 

  408. Kusumi E, Arakawa A, Kami M etc. Visual disturbance due to retinal edema as a complication of imatinib. Leukemia 2004;18(6):1138–1139.

    Google Scholar 

  409. Fraunfelder FW, Solomon J, Druker, BJ et al. Ocular side-effects associated with imatinib mesylate (Gleevec). J Ocul Pharmacol Ther 2003;19(4):371–375.

    Article  PubMed  CAS  Google Scholar 

  410. Cohen MH, Williams G, Johnson JR et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 2002;8(5):935–942.

    PubMed  CAS  Google Scholar 

  411. Hotte SJ, Winquist EW, Lamont E et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol 2005;23(3):585–590.

    Article  PubMed  CAS  Google Scholar 

  412. Pollack IF, Jakacki RI, Blaney SM et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro-oncol 2007;9(2):145–160.

    Article  PubMed  CAS  Google Scholar 

  413. Song KW., Rifkind J, Al-Beirouti B et al. Subdural hematomas during CML therapy with imatinib mesylate. Leuk Lymphoma 2004;45(8):1633–1636.

    Article  PubMed  CAS  Google Scholar 

  414. Escudier B, Eisen T, Stadle, WM. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125–34.

    Article  PubMed  CAS  Google Scholar 

  415. Kane RC, Farrell AT, Saber H et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 2006;12(24):7271–7278.

    Article  PubMed  CAS  Google Scholar 

  416. Govindarajan R, Adusumilli J, Baxter DL et al. Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43–9006. J Clin Oncol 2006;24(28):e48.

    Google Scholar 

  417. Perez-Ruixo JJ, Chen W, Zhang S et al. Exposure–toxicity relationships for tipifarnib in cancer patients. Br J Clin Pharmacol 2007;64(2):219–232.

    Article  PubMed  CAS  Google Scholar 

  418. Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 2001;97(11):3361–3369.

    Article  PubMed  CAS  Google Scholar 

  419. Rao S, Cunningham D, de Gramont, A. et al. Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol 2004;22(19):3950–3957.

    Google Scholar 

  420. DiPaola RS and Schuchter, L. Neurologic protection by amifostine. Semin Oncol 1999;26(2 Suppl 7):82–88.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Jörg Dietrich MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patrick Y. Wen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. School of Medicine, University of Virginia, Charlottesville, VA

    David Schiff MD

  2. Center for Neuro-Oncology Dana-Farber/Brigham and Women’s Cancer Center and Department of Neurology, Brigham and Women’s Hospital, Boston, MA

    Santosh Kesari MD, PhD  & Patrick Y. Wen MD  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press, Totowa, NJ

About this chapter

Cite this chapter

Dietrich, J., Wen, P.Y. (2008). Neurologic Complications of Chemotherapy. In: Schiff, D., Kesari, S., Wen, P.Y. (eds) Cancer Neurology In Clinical Practice. Humana Press. https://doi.org/10.1007/978-1-59745-412-4_17

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-412-4_17

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-983-3

  • Online ISBN: 978-1-59745-412-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation